Losing weight is a challenge for many, especially for the obese, but certain approved drugs by the U.S. Food and Drug Administration (FDA) can help, with a recent approval making its way into the market. Enter Eli Lilly and Company's "tirzepatide," a new obesity drug that promises massive things for weight loss, saying that it can help shed as much as 20 percent of a person's total mass. 

It is also claiming massive benefits from its clinical trials, with a competitor that is long-known in the market, Wegovy, also offering significant weight loss effects. 

FDA Approves a New Obesity Drug: tirzepatide

The FDA has approved a new drug called "Zepbound," with its clinical drug name known as "tirzepatide," and it is an injection shot centering on chronic weight management in adults with obesity. It is also applicable for people who are overweight, centering on the body mass index, or those with at least one weight-related condition including high blood pressure, type 2 diabetes, or high cholesterol said the agency. 

This drug approval was said to be an answer to the increasing rates of both obesity and overweight in the United States according to John Sharretts, M.D., the director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research.  

Read Also: Ingredient Found in Citrus-Flavored Soda Facing USFDA Ban

Lose Weight with the Right Lifestyle and Drug

With the right lifestyle centering on physical activities like exercising and workout, alongside a proper diet, this drug can help a person lose weight. According to its clinical trial results, this can help lose as much as 20 to 25 percent of a person's weight, with the requirements of diet and exercise met. 

"Tirzepatide, the active ingredient in Zepbound, is already approved under the trade name Mounjaro to be used along with diet and exercise to help improve blood sugar (glucose) in adults with type 2 diabetes mellitus," said the FDA. 

Obesity and Its Battle in the World

(Photo : Andres Ayrton from Pexels)

Many studies focus on obesity, and this is because it is considered by the National Health Institute (NHI) as a global epidemic that affects many age groups, communities, and more. In one research, it was found that obesity runs in the genes, linking it to one of the reasons for a person's urge to overeat, centering on a deficiency in a particular sequence in one's DNA.

It was widely known that the United States holds one of the highest rates of obesity in the world, with the global pandemic being one of the reasons for the higher rates found two years ago by a study. 

Obesity leads to massive health problems and is notorious for lowering the world's mortality rate, especially in areas or countries which is known for having many cases of this disease. However, that does not mean that it is untreatable, as the battle against obesity is still a significant focus, with Eli Lilly's latest FDA-approved tirzepatide drug looking to help, with massive promises in helping promote weight loss with the right lifestyle. 

Related Article: Surging Obesity Rates in US Raise Alarm: 22 States Hit 35% or Higher, Says CDC